Overcoming the challenge of antimicrobial resistance, two world-first products form a dual engine for anti-infection.
On May 22, Danuo Pharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as "Danuo Pharmaceutical") officially listed on the main board of the Hong Kong Stock Exchange with the stock code 6872.HK. The global offering consisted of 8,856,000 H shares, with an issue price of HK$75.70, raising a total of approximately HK$627 million and net proceeds of approximately HK$558 million.
The IPO was jointly sponsored by CITIC Securities (25.870, 0.00, 0.00%) and ABC International. Cornerstone investors included AMR Action Fund, Yuanhe Holdings, Orient Asset Management, and Junsheng Global, who subscribed for a total of approximately 3,082,450 shares, representing 34.81% of the total global offering. The international placement portion of the IPO was oversubscribed by 9.24 times, while the Hong Kong public offering was also highly popular, recording an oversubscription of 9,015 times, ranking second in the oversubscription list for Hong Kong main board IPOs since 2026.
Dr. Zhenkun Ma, founder, chairman of the board, and CEO of Danuo Pharmaceuticals, stated, “Our company has been deeply involved in the field of bacterial infections and bacterial metabolic diseases for over a decade. With our globally pioneering multi-target conjugation technology and core late-stage clinical products, we have become a rare gem in the antibacterial market. Leveraging our Hong Kong listing, we are embarking on a new journey of global development for innovative drugs, striving to become a leading company in the global treatment of bacterial infections and metabolic diseases. In the future, we will continue to focus on patients, address unmet clinical needs, continuously advance the research and commercialization of innovative drugs, overcome the challenges of drug-resistant infections, and provide better treatment options for patients worldwide.”
Founded in 2013, Dano Pharmaceuticals has been committed to addressing the global health threat of antimicrobial resistance and has invested heavily in solving common and major diseases related to gut bacterial metabolism. It has now established a differentiated pipeline of seven innovative projects around bacterial infections and bacterial metabolism-related diseases.
The core product, rifotenidazole (TNP-2198), is the world's first and only new molecular entity drug candidate for the treatment of Helicobacter pylori infection since its discovery in 1982. The prospectus shows that the infection rate of Helicobacter pylori in China is as high as 44.2%, affecting approximately 621.1 million people, and the problem of drug resistance is becoming increasingly serious, leading to a decline in eradication rates.
Riftenidazole, when used in combination with amoxicillin and a proton pump inhibitor (PPI), holds promise for eradicating Helicobacter pylori. The company has completed a Phase III head-to-head clinical trial in China comparing rifotenidazole triple therapy (RTT) with bismuth quadruple therapy (BQT). As part of the triple therapy regimen, rifotenidazole triple therapy achieved an eradication rate of 92.0% in modified intention-to-treat (mITT), superior to bismuth quadruple therapy's 87.9% (superiority p=0.034); the incidence of adverse events was only 37.3%, significantly lower than the control group's 53.2%, demonstrating significant advantages in both efficacy and safety. Furthermore, due to its more convenient administration, it is expected to significantly improve patient compliance and change the current state of Helicobacter pylori prevention and control.
Regarding the commercialization progress of rifotenidazole, the company submitted its NDA to the National Medical Products Administration (NMPA) in August 2025 and it was accepted, with approval expected by the end of 2026. In November 2024, the company signed an exclusive commercialization cooperation agreement for rifotenidazole in Greater China with Grand Life Science Group, fully leveraging Grand Life Science's strong sales network in areas such as gastrointestinal health management to accelerate product launch and promotion.
Another core product, rifaquinone (TNP-2092 injection), targets artificial joint infections (PJI) and acute bacterial skin infections (ABSSSI). It is the world's first novel molecular entity showing promise for biofilm infection treatment at clinically achievable doses. To date, no innovative antibacterial drugs for the treatment of PJI have been approved globally; rifaquinone is the only small-molecule candidate for PJI in clinical development. In the Phase II ABSSSI trial in the United States, the early clinical response rate in the mITT population reached 76.9%, superior to the 67.5% in the vancomycin control group, and the advantage was even more significant in the MRSA population (78.1% vs. 57.9%).
Both rifotenidazole and rifaquinone have received Fast Track designation and Qualified Infectious Disease Product (QIDP) designation from the US FDA. Rifaquinone has also received orphan drug designation from the FDA for use in PJI. The dual US and Chinese applications demonstrate a clear global strategy.
In addition, Dano Pharmaceuticals' pipeline includes oral TNP-2092 formulations for hepatic encephalopathy (HE) and diarrhea-predominant irritable bowel syndrome (IBS-D), and topical TNP-2092 formulations for diabetic foot infection (DFI). The oral TNP-2092 formulation has completed four Phase I and Phase II clinical trials in China, obtaining proof-of-concept clinical data that validated its safety and efficacy in treating hepatic encephalopathy.

https://finance.sina.com.cn/wm/2026-05-22/doc-inhytusq8588463.shtm l